Barclays Initiates Coverage on Talecris Biotherapeutics (TLCR) with an Equalweight
More News related to TLCR
- Talecris to Invest $268.7 Million to Expand its Manufacturing Facility in Clayton
- Barclays Initiates Coverage on Talecris Biotherapeutics (TLCR) with an Equalweight
- Notable Analyst Rating Changes 11/10: ADBE, ANN, FRPT, RAX Upgraded; ALU, CPST, PIKE, TRW Downgraded
- Morning Movers 11/10: UPG, CYD, PCLN, FLL, BZH Higher; RHIE, OPXT, PRKR, PIKE, MBI, SDTH Lower
- Several Brokerage Firms Initiate Coverage on Talecris Biotherapeutics (TLCR)
Barclays initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with an Equalweight rating. Price target $24.
To see more analyst ratings on TLCR Click Here.
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.
Related Categories
New CoverageStocks Mentioned
-0.75Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
